Pharmacoeconomics of antihypertensive drugs prescribed in a multispecialty hospital in South India

Article Sidebar

PDF
DOI: https://doi.org/10.22377/ajp.v8i3.356

Main Article Content

P. S. Dhivya
G. Swathy
Siddhartha Pal

Abstract

The main objective of this study is to evaluate the most cost‑effective therapy among the different group of antihypertensive
prescribed in a multispecialty hospital. According to inclusion and exclusion criteria, 104 hypertensive patients were
selected. Participants were interviewed at about the demographic data. Initial clinical assessment of blood pressure (BP) and
pulse rate were done. They were prescribed monotherapy either with angiotensin receptor blocker (ARB) (n = 7) or beta
blocker (BB) (n = 23) or calcium channel blocker (CCB) (n = 9). Angiotensin converting enzyme with BB (n = 27), ARB
with CCB (n = 17) and ARB with BB (n = 21) were prescribed in combination therapy. The cost of antihypertensive drugs
was calculated using incremental cost for “per mmHg†reduction and cost for “per patient†reaching target BP. The data are
analyzed using suitable statistical methods. ARB with BB shows significant reduction in BP. To maintain the targeted BP, BB
is found to be cost‑effective in both systolic BP (SBP) and diastolic BP (DBP) as well as in the reduction of “per mmHg†of
DBP. In case of reduction of “per mmHg†of SBP ARB is cost‑effective. Treatment of hypertension with BBs is cost‑effective.
Key words: Antihypertensive drugs, beta blockers, cost effectiveness

Downloads

Download data is not yet available.

Article Details

How to Cite
Dhivya, P. S., Swathy, G., & Pal, S. (2014). Pharmacoeconomics of antihypertensive drugs prescribed in a multispecialty hospital in South India. Asian Journal of Pharmaceutics (AJP), 8(3). https://doi.org/10.22377/ajp.v8i3.356
Issue
Vol. 8 No. 3 (2014): Jul-Sep
Section
Articles

This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.

References

Elliott WJ. The economic impact of hypertension. J Clin

Hypertens (Greenwich). 2003;53 Suppl 2:3‑13.

Gupta R, Rastogi P, Hariprasad D, Mathur B, Bhardwaj AK, Coronary

Heart Diseases and Risk Factors in Rural Populations of India. South

Asian J Prev Cardiol. Available from: http://www.sajprevcardiology.com/

vol7/vol7_4/coronaryheart.htm. [Last accessed on 2014 Jun 28].

Murray CJ, Lopez AD. Mortality by cause for eight regions of the world:

Global burden of disease study. Lancet 1997;349:1269‑76.

Redwood H. Hypertension, society, and public policy. Eur Heart J

;9:B13‑8.

Pierdomenico SD, Di Nicola M, Esposito AL, Di Mascio R, Ballone E,

Lapenna D, et al. Prognostic value of different indices of blood

pressure variability in hypertensive patients. Am J Hypertens

;22:842‑7.

Arenas‑Guzman R, Tosti A, Hay R, Haneke E, National Institue for Clinical

Excellence. Pharmacoeconomics – an aid to better decision‑making.

J Eur Acad Dermatol Venereol 2005;19 Suppl 1:34‑9.

Surendra G, Abasaheb B, Patil S, Kushare S. Pharmacoeconomics:

A Review. Asian J Pharm Clin Res 2009;2:15‑26.

Walley T, Davey P. Pharmacoeconomics: A challenge for clinical

pharmacologists. Br J Clin Pharmacol 1995;40:199‑202.

Fletcher A. Economics of hypertension control: A statement by the

world hypertension league. J Hum Hypertens 1994;8:789‑95.

Andersson F, Kartman B, Andersson OK. Cost‑effectiveness of

felodipine‑metoprolol (Logimax) and enalapril in the treatment of

hypertension. Clin Exp Hypertens 1998;20:833‑46.

Sur G, Sur M, Kudor‑Szabadi M, Sur L, Sporis D. Arterial hypertension

Prevalence of risk factors and morbid associations that increase

cardiovascular risk. J Clin Med Int J Hypertens 2011;5:34‑40.

By Y, Mr NG, Ag U. Prevalence, awareness, treatment, and control of

hypertension in rural areas of davanagere. Indian J Community Med

;35:138‑41.

Girerd X, Giral P. Risk stratification for the prevention of

cardiovascular complications of hypertension. Curr Med Res Opin

;20:1137‑42.

Catanzaro DF, Frishman WH. Angiotensin receptor blockers for

management of hypertension. South Med J 2010;103:669‑73.

Hilleman DE, Mohiuddin SM, Lucas BD Jr, Stading JA, Stoysich AM,

Ryschon K. Cost‑minimization analysis of initial antihypertensive

therapy in patients with mild‑to‑moderate essential diastolic

hypertension. Clin Ther 1994;16:88‑102.

Dias da Costa JS, Fuchs SC, Olinto MT, Gigante DP, Menezes AM,

Macedo S, et al. Cost‑effectiveness of hypertension treatment: A

population‑based study. Sao Paulo Med J 2002;120:100‑4.

Ulasi II1, Ijoma CK, Onwubere BJ, Arodiwe E, Onodugo O, Okafor C. High

prevalence and low awareness of hypertension in a market population

in enugu, Nigeria. Int J Hypertens. 2011;2011:869675.

Girerd X1, Giral P. Risk stratification for the prevention of cardiovascular

complications of hypertension. Curr Med Res Opin, 2004;20 :1137-42.